Nighttime Cough Research Articles

Efficacy and safety of Pranabb® syrup to reduce cough and improve sleep quality in children compared to usual recommended hydration measures

Background: Coughing is crucial for protecting the airways, but associated to unpleasant symptoms that often lead to pediatrician visits. Natural remedies like honey and essentials oils are being increasingly used to effectively relieve symptoms associated with cough. Objectives: Evaluate the efficacy and safety of Pranabb® cough syrup, an organic honey-based natural formulation tailored for pediatric patients, in relieving cough symptoms. Methods: One-week multicenter comparative clinical study of 50 children, 28 in the treatment group and 22 in the control group with supportive measures (increased hydration). Pediatrician appointments were scheduled at the baseline and on day 7, with a progress check call on day 3. Parents kept a daily cough diary. Results: Day 3 results show a significant decrease in daytime cough, night-time cough and global score more pronounced and statistically significant in the study group, although the more severe baseline level in the study group. On day 7, decrease in daytime and overall cough scores was greater in the study group (p<0.05). The frequency of awakenings due to coughing decreased on day 3 only in the study group (p<0.05) and on day 7 for both groups, although it was higher and more significant in the study group (-1.82 p<0.01 vs -1.25 p<0.05). In addition, the safety analysis confirms that the syrup is not toxic to children. Conclusion: Pranabb® Cough Syrup is safe and effective, reducing cough severity and nighttime awakenings in children and improving parents’ ability to sleep. More randomized clinical trials will be interesting to get more homogeneity between the two groups at baseline.

Tutt la tosse in una figura

Cough is the most common cause of unscheduled paediatric visits. The figure in the article shows the main causes of paediatric coughs differentiated by duration, quality (dry or wet) and night-time coughing. With these few simple key anamnestic elements (and espe- cially if confirmed and reinforced by being able to see, even in a simple video, the child coughing) a diagnosis may be made with reasonable certainty, saving specialist visits and diagnostic tests that are unlikely useful and potentially harmful.

Efficacy and tolerability of SEDIFLÙ in treating dry or productive cough in the pediatric population (SEPEDIA): A pilot, randomized, double-blind, placebo-controlled, multicenter clinical trial.

The aim of this trial was to assess the effectiveness of Sediflù, a medical device containing active herbal ingredients, on nocturnal and diurnal persistent coughs in children, with a duration of 3 to 7 days. Children with a dry and/or productive cough were enrolled in this prospective, interventional, multicenter, placebo-controlled, double-blind, randomized clinical study. Clinical efficacy was assessed through the evaluation of the soothing action of Sediflù against dry and/or productive coughing, both at night and during the day, and other effects of coughing associated with quality of sleep: frequency, child's quality of sleep, parental quality of sleep and severity. Treatment with Sediflù improved both night-time and day-time cough scores from day 2. The diurnal score also improved significantly in the Sediflù group at days 3 and 7. Sediflù syrup can be considered a valid treatment for cough management in younger children with upper respiratory tract infections, shortening the cough duration.

Effectiveness and safety of AROMAFORCE® junior cough syrup in pediatric patients with acute upper respiratory conditions

Aim: The purpose of this study was to evaluate the effectiveness and safety of Aromaforce® Junior Cough Syrup (AJCS) in treating acute upper respiratory tract infection-related coughs in children, and it served as a post-marketing clinical follow-up. Methods: Prospective, multicenter, open-label, controlled clinical investigation conducted under normal conditions of use to evaluate the antitussive effectiveness of a mucilage-based syrup in pediatric patients (aged 2 to 12 years) as compared to increased hydration measures (control group), with a 1-week follow-up. Likert severity scores were used to evaluate coughs and related symptom severity. Results: The results demonstrate that AJCS effectively reduces cough severity, including daytime and night-time cough, and the number of times the child was woken up, particularly within the first three days, surpassing the effectiveness of hydration measures. The results of the degree of satisfaction with AJCS show that the majority of physicians and parents had positive feedback. Furthermore, the safety analysis confirms the syrup's non-toxic nature in children. However, the initial differences in baseline characteristics between the study and control groups, with the study group exhibiting higher combined cough scores, limit the strength of the evidence. Conclusions: This study provides further evidence supporting the efficacy and safety of AJCS in the treatment of cough associated with acute upper respiratory tract infections in children. Further randomized studies may provide further evidence of the efficacy and safety of AJCS.

Возможности профилактики рецидивов обструктивного бронхита у детей в сезон острых респираторных инфекций

The possibility of preventing episodes of bronchial obstruction (BO) in order to reduce the risk of bronchial asthma formation attracts the attention of many researchers and doctors. Ammonium glycyrrhizinate (Reglisam, "VIFITECH") is of practical interest in the search for promising anti-inflammatory drugs in this matter. Patients and methods. The study involved 110 children aged 3 to 7 years with symptoms of acute obstructive bronchitis, who had a history of at least 2 episodes of BO in the previous 6 months. Formed: the comparison group (n = 30) – received inhalations of ICS up to 1 month and SABA on demand and the main group (Reglisam) (n = 80) – additionally, the drug was prescribed to Reglisam for 24 weeks. The duration of patient follow-up was 24 weeks, five visits to the clinic were performed (day 1, week 1, week 4, week 12, week 24) and two telephone contacts (weeks 8 and 16). During visits, the following indicators were evaluated: computed bronchophonography (CBFG), cough on a visual analog scale (VAS), and the volume of additional therapy. Results. In the main Reglisam group, by the 3rd day of treatment, the intensity of daytime and nighttime cough was 30% lower relative to the comparison group (1.92 ± 0.05 vs 2.74 ± 0.03 points and 1.8 ± 0.04 vs 2.6 ± 0.04 points, respectively (p < 0.05)), 70% of patients in the Reglisam group showed a decrease of CBFG to normal values, the proportion of such patients in the comparison group did not exceed 50%. In the Reglisam group, the average duration of BO was 38% less relative to the comparison group (6.9 ± 0.2 vs 11.2 ± 0.8 days, (p < 0.05)), the duration of SABA use was 46% less relative to the comparison group (4.13 ± 0.7 vs 7.62 ± 0.8 days, p < 0.05). When patients were followed up for the next 23 weeks in the main Reglisam group, the average number of ARI was 41% and BO was 83% less relative to the comparison group (1.3 ± 0.05 vs 2.2 ± 0.1 cases, 0.3 ± 0.001 vs 1.8 ± 0.21, respectively (p < 0.05). In the Reglisam group, the average duration of ARI cases did not exceed 6.6 ± 0.2 days, in the comparison group it was significantly 40% longer (10.9 ± 0.4 days (p < 0.05)). In the treatment of ARI in the main Reglisam group, the need for the use of ICS and SABA was 2 times lower relative to the comparison group (35% vs 77% and 50% vs 100%, respectively (p < 0.05). Conclusion. The inclusion of Reglisam in the complex therapy of acute obstructive bronchitis contributed to a rapid and effective reduction in the intensity of cough symptoms by the 3rd day of treatment, reducing the duration of use of SABA and the duration of the disease in general. In dynamics, against the background of a prophylactic course of Reglisam (23 weeks) during the epidemiological season of ARI, there was a significant decrease in the frequency of ARI, virus-induced relapses of OB and, as a consequence, the need for the use of ICS and SABA. Key words: coronavirus infection, COVID-19, post-COVID syndrome, children, rehabilitation, bronchial asthma, ammonium glycyrrhizinate, glycyrrhizic acid

Patient preferences for the treatment of chronic cough: a discrete choice experiment

BackgroundChronic cough is common, negatively affects quality of life and has limited treatment options. Inhibition of purinergic signalling is a promising therapeutic approach but is associated with taste-related adverse effects....

Trajectory analysis of rhinitis in a birth cohort from lower-income New York City neighborhoods

Rhinitis is a prevalent, chronic nasal condition associated with asthma. However, its developmental trajectories remain poorly characterized. We sought to describe the course of rhinitis from infancy to adolescence and the association between identified phenotypes, asthma-related symptoms, and physician-diagnosed asthma. We collected rhinitis data from questionnaires repeated across 22 time points among 688 children from infancy to age 11 years and used latent class mixed modeling (LCMM) to identify phenotypes. Once children were between ages 5 and 12, a study physician determined asthma diagnosis. We collected information on the following asthma symptoms: any wheeze, exercise-induced wheeze, nighttime coughing, and emergency department visits. For each, we used LCMM to identify symptom phenotypes. Using logistic regression, we described the association between rhinitis phenotype and asthma diagnosis and each symptom overall and stratified by atopic predisposition and sex. LCMM identified 5 rhinitis trajectory groups: never/infrequent; transient; late onset, infrequent; late onset, frequent; and persistent. LCMM identified 2 trajectories for each symptom, classified as frequent and never/infrequent. Participants with persistent and late onset, frequent phenotypes were more likely to be diagnosed with asthma and to have the frequent phenotype for all symptoms (P< .01). We identified interaction between seroatopy and rhinitis phenotype for physician-diagnosed asthma (P= .04) and exercise-induced wheeze (P= .08). Severe seroatopy was more common among children with late onset, frequent and persistent rhinitis, with nearly 25% of these 2 groups exhibiting sensitivity to 4 or 5 of the 5 allergens tested. In this prospective, population-based birth cohort, persistent and late onset, frequent rhinitis phenotypes were associated with increased risk of asthma diagnosis and symptoms during adolescence.

Examining the potential risk factors for variable airflow limitation in patients recovering from SARS-CoV-2 Omicron variant infection: A case-control study

The Omicron strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally. However, it remains uncertain whether variable airflow limitation (VAL) occurs during the recovery phase after contracting the Omicron variant. To address this question, we conducted a study to examine the occurrence of VAL in patients infected with the Omicron variant (BA.1) of SARS-CoV-2, and we also investigated the potential risk factors associated with this phenomenon. We summarized and analyzed data taken from the electronic health records of recovering patients who had contracted the Omicron variant. The information was obtained from the Shuixi Branch of our Hospital during the period from January 22 to February 24, 2022. We focused on examining the occurrence of VAL and identifying the associated risk factors among these patients. In this case-control study, a total of 176 patients were enrolled. The occurrence of VAL was observed in 9.66% (17 individuals). Patients with VAL showed significantly elevated levels of the modified Borg dyspnea score, daytime cough score, night-time cough score, chest computed tomography severity score, and Treg ratio compared to those without VAL. Additionally, patients with VAL had a lower 6MWD value compared to those without it. Logistic regression analysis demonstrated that the modified Borg dyspnea score independently increased the risk of Omicron infection with VAL, with an odds ratio of 3.375, and a 95% confidence interval ranging from 1.537 to 7.408, with a P-value of .002. There is a possibility of experiencing VAL in certain patients recovering from the SARS-CoV-2 Omicron variant infection. The modified Borg dyspnea score has been identified as a standalone risk factor for the occurrence of VAL in SARS-CoV-2 Omicron infection.

Objective and self-reported evidence of dextromethorphan antitussive efficacy in children, aged 6-11 years, with acute cough due to the common cold.

To determine objective and subjective endpoints most suitable for evaluating antitussive efficacy of dextromethorphan hydrobromide (DXM) in children. Spontaneous resolution of acute cough and large placebo effects are impediments to evaluating antitussive efficacy. Another impediment is paucity of age-appropriate, validated cough assessment tools. This was a multiple-dose, double-blind, placebo-controlled, randomized, pilot clinical study in children, aged 6-11 years, with cough due to the common cold. Eligible subjects met entry criteria and qualified by completing a run-in period where coughs were recorded with a cough monitor after they were dosed with sweet syrup. They were subsequently randomized to receive DXM or placebo over 4 days. Coughs were recorded during the initial 24 h; subjective assessments of cough severity and frequency were self-reported daily during treatment. Data from 128 evaluable subjects (67 DXM; 61 placebo) were analyzed. Total coughs over 24-hours (primary endpoint) and cough frequency during daytime were reduced by 21.0% and 25.5%, respectively, with DXM relative to placebo. Also, greater reductions in cough severity and frequency were self-reported with DXM. These findings were statistically significant and medically relevant. No effects were detected between treatments for nighttime cough rates or impact of cough on sleep. Multiple doses of DXM and placebo were generally well-tolerated. Evidence of DXM antitussive efficacy was shown in children using objective and subjective assessment tools validated in pediatric populations. Diurnal variation of cough frequency over 24 h reduced the assay sensitivity needed to detect treatment differences at nighttime, as coughs/hour decreased during sleep for both groups.

Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials.

The efficacy and safety of gefapixant in adults with chronic cough remain unclear. Our objective was to assess the efficacy and safety of gefapixant using updated evidence. MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase databases were searched from inception through September 2022. Subgroup analysis based on dose of gefapixant (i.e. ≤20, 45-50 and ≥100 mg twice daily for low, moderate and high doses, respectively) was performed to explore a potential dose-dependent effect. Five studies involving seven trials showed the efficacy of moderate- or high-dose gefapixant for reducing objective 24-h cough frequency (estimated relative reduction 30.9% and 58.5%, respectively) (i.e. primary outcome) and awake cough frequency (estimated relative reduction 47.3% and 62.8%, respectively). Night-time cough frequency was only reduced with high-dose gefapixant. Consistently, the use of moderate- or high-dose gefapixant significantly alleviated cough severity and improved cough-related quality of life, but increased the risk of all-cause adverse events (AEs), treatment-related AEs and ageusia/dysgeusia/hypogeusia. Subgroup analysis showed dose dependency in both efficacy and AEs with a cut-off dose being ≥45 mg twice daily. This meta-analysis revealed dose-dependent efficacy and adverse effects of gefapixant against chronic cough. Further studies are required to investigate the feasibility of moderate-dose (i.e. 45-50 mg twice daily) gefapixant in clinical practice.

Novel Technology to Identify Times of Peak Nighttime Cough Frequency in Severe Asthma

Patients with asthma frequently report nighttime cough as a primary symptom that disrupts sleep. New digital technologies permit passive monitoring during nighttime sleep hours and allow for the identification and quantification of the occurrence of cough episodes.

Objective Assessment of Nighttime Cough in Uncontrolled Asthma Does Not Correlate with Patient Self-Reported Symptoms

Objective Assessment of Nighttime Cough in Uncontrolled Asthma Does Not Correlate with Patient Self-Reported Symptoms

Clinical efficacy of mucoactive therapy with 7% hypertonic saline in patients with acute bronchitis

Introduction. Respiratory viruses are the overwhelming etiological agents of acute bronchitis in adults. However, the routine management of such patients often includes the prescription of antibiotics. The primary treatment for acute bronchitis is the administration of mucoactive agents to liquefy and improve sputum flow.The aim is to investigate the efficacy and safety of 7% hypertonic solution in patients with acute bronchitis.Materials and methods. A total of 50 patients were enrolled, of whom 25 participants received Ingasalin® forte (7% hypertonic solution) and 25 patients formed a second control group in which participants received other drugs as mucoactive therapy (routine clinical practice).Results. Severity of productive cough in Group 1 patients equaled 2,24 ± 0,4 points, in Group 2 – 2,4 ± 0,5 points. On the 4th day there was a significant reduction in the severity of both daytime and nighttime cough in the vast majority of patients. At the same time, severity of daytime cough on the 4th day of treatment in Group 1 was equal to 1,36 ± 0,5, and in Group 2 – to 1,7 ± 0,5. During the same period, the number of AB patients with a significant reduction in cough severity in group 1 was 16 (64%), while in group 2–8 (32%).Conclusion. Thus, the use of 7% hypertonic solution was accompanied by a good effect in the form of a pronounced cough regression in patients with AB.

Effect of Ayurvedic Polyherbal Compound (Syrup Kasahara Dashemani) in the Management of Vataja Kasa (Acute Cough) in Children – An Open-label Single-arm Clinical Study

ABSTRACT Background: Cough is one of the most common clinical presentations encountered frequently in the pediatric population and is correlated with Kasa Roga in Ayurveda. Kasa Roga (cough) is distressing to children and hampers their quality of life. Vataja Kasa (acute cough) if left untreated becomes chronic and distressing to both the child and the parents. Various ayurvedic formulations with cough-suppressing effects have been documented in classical texts that are cost-effective; Kasahara Dashemani is one such ayurvedic polyherbal compound mentioned by Acharya Charaka, possessing antitussive properties that are also evidenced by previous studies. Objectives: The objective of this study was to assess the efficacy of Syrup Kasahara Dashemani on classical cardinal features of Vataja Kasa (acute cough), cough scores, and hematological parameters. Materials and Methods: The present study was an interventional prospective, open-label, single-arm clinical trial in which 30 children between the age group of 5 and 15 years presenting with classical cardinal features of Vataja Kasa (acute cough) were administered with syrup Kasahara Dashemani orally in various age-dependent doses calculated by using Young’s formula, every 6 h for 1-month duration. Assessment criteria included six classical cardinal features of Vataja Kasa, daytime and nighttime cough scores, and hematological investigations. Results: On assessing the outcome parameters, significant improvement was observed in all the six classical cardinal features of Vataja Kasa (acute cough), daytime and nighttime cough scores (P &lt; 0.0001), eosinophil count (P &lt; 0.05), absolute eosinophil count (P &lt; 0.05), and erythrocyte sedimentation rate (P &lt; 0.05) in all the study subjects. Conclusion: Syrup Kasahara Dashemani can help alleviate Vataja Kasa (acute cough) in the pediatric population.

Cigarette‒E-cigarette Transitions and Respiratory Symptom Development

E-cigarette use is associated with pulmonary inflammation, functional respiratory changes, and chronic lung disease. Most population-level E-cigarette research has utilized point-in-time measures of E-cigarette exposures, which may not generalize to adults who transition between cigarettes and E-cigarettes. Data obtained from the Population Assessment of Tobacco and Health study were collected from 2013 to 2019 and analyzed in 2022. Three observations were created per respondent, with exposure intervals assessed over Waves 1-2, 2-3, and 3-4. Each wave of the exposure interval was classified as nonuse, exclusive E-cigarette use, exclusive smoking, or dual use, producing 16 possible cigarette‒E-cigarette transitions. The association between transitions and both dry nighttime cough and wheeze symptom development during follow-up were assessed using mixed-effects Poisson models. Among 33,231 observations from 13,528 unique participants, transitioning from nonuse to exclusive E-cigarette use was associated with 1.62 times higher incidence rate of wheeze (incident rate ratio=1.62; 95% CI=1.12, 2.34) than persistent nonuse. There was no change in reported dry nighttime cough (incident rate ratio=0.84; 95% CI=0.52, 1.35) or wheeze (incident rate ratio=0.87; 95% CI=0.52, 1.46) in individuals who switched from cigarettes to E-cigarettes, whereas transitioning from dual use to E-cigarette use was associated with large reductions in both symptoms (incident rate ratio=0.58; 95% CI=0.39, 0.87 and incident rate ratio=0.36; 95% CI=0.20, 0.63, respectively). E-cigarette initiation among nonusers is associated with increased respiratory morbidity. Further research should assess the risks and benefits of E-cigarette‒assisted cigarette cessation given the reduction in symptom development rates among dual use to E-cigarette switchers.

ROLE OF HONEY IN NOCTURNAL COUGH IN PAEDIATRIC PATIENTS: A CRITICAL REVIEW

Acute respiratory infections (A.R.I.s) remain the leading cause of childhood morbidity and mortality in India, causing an estimated 4 million pneumonia and 1 million fatalities annually. Except during the neonatal period, A.R.I.s are the primary cause of illness and death in children under five, with an average of three to six episodes per year. The most prevalent, unpleasant, and early warning sign of A.R.I.s is cough. Cough caused by URTIs or cough without preceding infection causes parental worry in early childhood and is a primary cause of outpatient visits. Cough can impact one's quality of life, cause anxiety, and disrupt children's sleep; therefore, parents frequently seek a rapid remedy for their children. Since antiquity, honey and its numerous remedies have been used to treat coughs effectively. Honey is also essential to paediatric treatment in the Ayurveda medical system. Honey is said to cure various diseases and is recommended in multiple situations as the primary medicine as anupana, sahapana, and on occasion. To support the child's entire physical and cognitive development, Ayurveda encouraged the use of honey in the 'lehana' form, along with ghee (clarified butter oil), other herbal medicines, and Suvarna bhasma. When used to treat a night-time cough, honey gives significant symptomatic relief regarding cough severity, episode length, and insomnia. Honey's mucolytic, anti-inflammatory, and bronchodilator qualities provide comfort from nocturnal coughing, and multiple clinical research has shown that honey is more helpful in lowering cough frequency, intensity, and the impact of cough on sleep.

Results of an open observational multicenter study of the effectiveness and tolerability of levodropropizine in comparison with standard antitussive therapy (real practice) in the treatment of patients with COVID-19

Cough is one of the most common symptoms of COVID-19 (COronaVIrus Disease-2019), occurring in more than 70% of cases. The cough associated with the new coronavirus infection tends to be non-productive and requires symptomatic antitussive therapy. However, at present, there is insufficient data on the effectiveness of various antitussive agents in COVID-19.The aim. Analysis of the clinical and economic efficiency and safety of the use of levodropropizin in comparison with standard symptomatic therapy of patients with a new coronavirus infection COVID-19 in the real-life clinical setting.Methods. An open observational multicenter study was conducted in Moscow, Krasnodar, Kazan, Voronezh, and Rostov-on-Don. The study enrolled 250 inpatient COVID 19 patients (1 875 years) with complaints of dry unproductive cough which required symptomatic treatment. The main group included 150 people who received levodropropizine according to the label. The comparison group received other antitussive drugs. Each patient was examined on days 1, 4 and 8. The examination included collection of the current complaints and medical history, physical examination and assessment of the intensity of cough using day and night cough assessment scale using a 6-point scale for assessing daytime and nighttime cough and a visual analog scale (VAS).Results. In the main group, significant differences were revealed between the baseline and Day 4 in the form of a significant decrease in the severity of daytime cough (р = 0.002); significant differences were found between Day 4 and Day 8 for both daytime (р = 0.002) and nocturnal cough (р = 0.0001). The comparison group showed positive dynamics, but significant differences were seen only between the baseline and Day 8 at night (р = 0.001). The severity of cough on VAS scale in the main group differed significantly on Day 8 as compared to baseline (р = 0.001), as well as between Day 4 and Day 8 (р = 0.002). No significant differences were seen in the comparison group. No adverse effects were observed during treatment with levodropropizine.Conclusion. Levodropropizine has shown high efficacy and safety in the treatment of dry unproductive cough in comparison with standard symptomatic therapy in the form of a significant decrease in cough intensity according to both scales, starting from the 4th day.

Tobacco Product Use and Functionally Important Respiratory Symptoms Among US Adolescents/Young Adults.

The relation between respiratory symptoms and the range of tobacco product use among US adolescents/young adults is not yet clear. This cross-sectional analysis examines tobacco product use and respiratory symptoms in a nationally representative sample of 21,057 adolescents/young adults aged 12-24 years from Wave 4 (2016-17) of the Population Assessment of Tobacco and Health Study. Presence of functionally important respiratory symptoms was defined by questions regarding wheezing and nighttime cough at a cutoff score associated with poorer functional health status. Past-30-day tobacco use was analyzed 2 ways: never-tobacco users (reference) versus combustible users, noncombustible-only users, and former users; or frequency of use of cigarettes and/or e-cigarettes. Weighted Poisson regression adjusted for past-30-day marijuana use, secondhand smoke exposure, and asthma. Functionally important respiratory symptoms were present in 10.0% overall: 13.8% of combustible users, 9.0% of noncombustible users, 8.2% of noncurrent users and 9.7% of never users. Functionally important respiratory symptoms were associated with combustible tobacco use (relative risk [RR]=1.52[95% CI 1.29, 1.80]), marijuana use (RR=1.54[1.34, 1.77]) and secondhand smoke exposure (RR=1.04[1.03, 1.05]). Higher cigarette smoking frequency was also associated with functionally important respiratory symptoms for frequency categories >14 days/month (eg, RR=1.93[1.50, 2.49] for 15-29 days/month). Frequency of e-cigarette use was not associated with functionally important respiratory symptoms. During 2016-17, smoking cigarettes, marijuana use, and secondhand smoke exposure were cross-sectionally associated with functionally important respiratory symptoms in adolescents/young adults. Risk increased with increased frequency of cigarette use but not e-cigarette use. Given changes to contemporary e-cigarettes and use, findings may not generalize to newer products.

Efficacy and Safety of a Novel Gummy Formulation for the Management of Cough in Adults: Double Blind, Randomized, Placebo-Controlled Trial

The cough is one of the most common medical complaints affecting the general population. It is well known that persisting cough negatively affects subjects’ quality of life (QoL) and sleep quality. The aim of the current double blind, randomized, placebo-controlled, pilot study was to assess the effectiveness of a novel medical device in gummy format in reducing cough and improving QoL in adult subjects with acute persisting cough. Forty subjects were enrolled and randomized into two arms according to the treatment. Both the investigational product (IP) and placebo were administered orally, three times per day for 10 consecutive days. Cough symptoms and severity were measured by the Cough Clinical Score (CCS) consisting of a 6-point Likert scale, Leicester Cough Questionnaire (LCQ) and cough severity visual analogue scale (VAS). QoL was rated using the SF-36 (short form) questionnaire. Significant improvements were seen both in the daytime and nighttime cough score after 5 days and at the end of treatment in the IP group but not in those subjects taking the placebo. QoL and sleep disturbances were ameliorated significantly in the IP group only. In conclusion, IP was found safe, well-tolerated and effective in the management of persisting cough in adults.

The Fun Mother and Her Lovely Assistant

The Fun Mother and Her Lovely Assistant